← Eichor
Study identifier: NCT05580861 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

Condition: Acute Myeloid Leukemia  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhasePhase 1/Phase 2
Planned participants64
Who can joinAll sexes, 60 Years to no upper limit
Healthy volunteersNo

About this study

Acute myeloid leukemia (AML) is a heterogeneous clonal myeloid neoplasm where abnormal proliferation and impaired differentiation of hematopoietic stem and myeloid progenitor cells impedes normal hematopoiesis. Sulfasalazine (SSZ) is a broadly available, well tolerated anti-inflammatory medicine approved for the treatment of ulcerative colitis and rheumatoid arthritis. Intact SSZ, but not its metabolites 5-aminosalicylic acid and sulfapyridine, competitively inhibits xCT.21 SSZ is thus an ideal candidate for drug repurposing in AML.The purpose of this phase I study is to evaluate the safety and feasibility of such strategy, provide preliminary signals of efficacy, and identify potential biomarkers

This description comes directly from the study's public registry record.

Talk to the study team

Raphaël Itzykson, Pr  ·  1 42 49 96 43  ·  raphael.itzykson@aphp.fr

Jérôme Lambert, Pr  ·  142499742  ·  jerome.lambert@u-paris.fr

Always discuss trial participation with your own doctor first.

Locations (13)

CHU AmiensAmiens, FranceNot Yet Recruiting
Hôpital AvicenneBobigny, FranceNot Yet Recruiting
CHU CaenCaen, FranceNot Yet Recruiting
CHU Henri MondorCréteil, FranceRecruiting
Centre Hospitalier Lyon Sud, LyonLyon, FranceRecruiting
Hôpital de la Conception, AP-HMMarseille, FranceNot Yet Recruiting
CHU NiceNice, FranceRecruiting
AP-HP Hôpital Saint LouisParis, FranceRecruiting
AP-HP Hôpital CochinParis, FranceRecruiting
Centre Henri BecquerelRouen, FranceNot Yet Recruiting
CHU ToursTours, FranceRecruiting
CH MignotVersailles, FranceRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05580861